Literature DB >> 10430311

An effective pre-operative chemoimmunotherapy regimen against advanced gallbladder carcinoma: a case report.

H Hasegawa1, H Ueo, S Nanbara, K Tsuji, M Mori, T Akiyoshi.   

Abstract

We designed a chemoimmunotherapy regimen with a single dose of mitomycin C (MMC) followed by subsequent OK-432 injections, since the ability of peripheral blood mononuclear cells (PBM) to generate OK-432 activated killer cells had previously been shown to be augmented by MMC in cancer patients. We herein report on a case with far advanced gallbladder carcinoma who demonstrated a remarkable response to this chemoimmunotherapy, and thus underwent a curative resection. A 67 year-old Japanese woman was diagnosed as having gallbladder carcinoma with invasion to the liver and portal vein, as well as obvious lymph node metastasis. Since these findings suggested the tumor to be unresectable at that time, our chemoimmunotherapy regimen with MMC and OK-432 was administered. After four courses of therapy, a computed tomography (CT) scan revealed the disappearance of both tumor invasion to the surrounding organs and lymph node metastasis, which therefore prompted us to attempt a radical tumor resection. The histology of the resected specimen revealed that the majority of cancer cells had been killed by the pre-operative therapy and that only remnants of viable cancer cells were found in a part of the neck of the gallbladder and in 2 regional lymph nodes. This experience thus suggests the effectiveness of our chemoimmunotherapy regimen against gallbladder carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430311

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  2 in total

1.  A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.

Authors:  Jae-Yong Cho; Ji-Sun Nam; Mi-Suk Park; Jeong-Sik Yu; Yong-Han Paik; Se-Joon Lee; Dong-Ki Lee; Dong-Sup Yoon
Journal:  Yonsei Med J       Date:  2005-08-31       Impact factor: 2.759

2.  A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.

Authors:  D C Doval; J S Sekhon; S K Gupta; J Fuloria; V K Shukla; S Gupta; B S Awasthy
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.